Reorganization of the cytoskeleton is necessary for apoptosis, proliferation, migration,
development and tissue repair. However, it is well established that mutations or overexpression of …

Establishing causal links between inherited polymorphisms and cancer risk is challenging.
Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold …

Infrequently mutated genes comprise most of the mutational burden in breast tumors but are
poorly understood. In vivo CRISPR screening identified functional tumor suppressors that …

Over the past 20 years, the Ste20-like kinase (SLK; also known as STK2) has emerged as a
central regulator of cytoskeletal dynamics. Reorganization of the cytoskeleton is necessary …

Mutational signatures represent a genomic footprint of endogenous and exogenous mutational
processes through tumor evolution. However, their functional impact on the proteome …

Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic
target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have …

Background Breast cancer is a highly heterogeneous disease with multiple drivers and complex
regulatory networks. Periostin (Postn) is a matricellular protein involved in a plethora of …

It is widely assumed that all normal somatic cells can equally perform homologous recombination
(HR) and non-homologous end joining in the DNA damage response (DDR). Here, we …

Background Approximately 5–10% of HER2-positive breast cancers can be defined by low
expression of the Ste20-like kinase, SLK, and high expression of SOX10. Our lab has …

The Androgen Receptor (AR) has recently garnered a lot of attention as a potential biomarker
and therapeutic target in hormone-dependent cancers, including breast cancer. However, …